How supplier stratification governance models de-risked raw material supply to support advancement of BlueRock’s pipeline into the clinic
Cell and Gene Therapy Insights 2026; 12(7), 819–823
10.18609/cgti.2026.100
Published: 9 September
Commentary
Biotechnology and life science companies interact in a specialized supply chain within a regulated environment. Factors such as cold chain/temperature-controlled logistics, limited shelf life of raw materials (e.g., cell culture media/reagents category), QC testing and QA release criteria are part of regular operations. Additionally, Good x Practice core principles, guidelines, and requirements touch all areas of the organization (i.e., Good Documentation Practice, Good Manufacturing Practice, Good Distribution Practice (GDP), etc.) to ensure drug products and/or medical devices are safe, effective, and high quality for patients
What you will learn
01
Why treating raw material suppliers as purely transactional left BlueRock unable to expedite orders or secure allocation during Phase 1, and why that approach couldn't scale for the eight to ten times larger Phase 3 trial
02
How BlueRock selected a Supplier Pyramid stratification model over alternatives like the Kraljic Matrix, scoring suppliers on pipeline impact, total spend, and criticality to sort them into Tier 1–3 segments
03
How a two-level governance structure, monthly operational meetings plus semi-annual steering reviews for Tier 1 suppliers, restored on-time-in-full delivery within a single quarter and de-risked the exPDite-2 trial
Key interests